Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2205922 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of G6PD deficiency and submicroscopic malaria parasites carriage in malaria hotspot area in Northwest, Tanzania.
Malar J
December 2023
Mwanza Centre, National Institute for Medical Research, Mwanza, Tanzania.
Background: The use of primaquine for mass drug administration (MDA) is being considered as a key strategy for malaria elimination. In addition to being the only drug active against the dormant and relapsing forms of Plasmodium vivax, primaquine is the sole potent drug against mature/infectious Plasmodium falciparum gametocytes. It may prevent onward transmission and help contain the spread of artemisinin resistance.
View Article and Find Full Text PDFHigher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
N Engl J Med
July 2022
Mahidol Oxford Tropical Research Unit, Bangkok, Thailand
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
N Engl J Med
July 2022
Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Where the Rubber Meets the Road - Research in the Amazon.
NEJM Evid
May 2022
Laboratório de Pesquisas Básicas em Malária, Instituto Evandro Chagas, Ministério, da Saúde do Brasil, Ananindeua, Pará State, Brazil.
Antimalarial Research in the AmazonMany patients who receive treatment for vivax malaria in the Americas present with recurrent infection within six months after completing treatment. This raises an important question: Does higher-dose primaquine work better than the treatment currently used in the Americas to prevent recurrences? This Clinical Trial Case Study describes the behind-the-scenes story of a randomized trial to evaluate antimalarial treatment efficacy in the Brazilian Amazon.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!